GlucoScanner, the new non-invasive biosensor for blood glucose levels, working through optical technology and signal processing methods, after the crowdfunding campaign launched in January, can finally step in the finalization phase at the Dynamic Brain Labs LLC in Tokyo, Japan.
The device was conceived to revolutionize the world of thousands of diabetics who are currently forced to check the glucose levels in their blood daily. GlucoScanner, in fact, does not require any invasive procedure such as continuous finger pricking, avoiding arm patches and additional costs for disposable products.
An integrated system of sensors, mobile apps, and data services has been designed to enable global scale research of diabetes aiming to further understanding and prevent health-related crises. Besides measuring the glucose level, GlucoScanner can monitor other body parameters such as heartbeat and blood oxygen concentration, in order to have a continuous, clear frame of the patient physical status.
Thanks to the Cloud Software and the mobile app, GlucoScanner is able to alert caretakers and selected relatives or friends in case of emergency. All the necessary data for monitoring general health status can be collected. This system, developed by Stefano Valenzi and Peter Jurica, can be used to improve data access and ultimately to facilitate communication for the scientific community and health professionals.
GlucoScanner employs non-standard light frequencies in the infrared spectrum. Dynamic Brain Labs has developed a new way to assess tissue light absorption data. The device combines light absorption information with other physiological data and individual physical features; thus allowing the research team to solve some of the well-known problems linked to optical technology, such as differences in skin pigmentations. A simple automated calibration procedure performed on individuals’ fingers will guide the user through the GlucoScanner setup in order to optimize the device performance.
In the first phase, GlucoScanner has been tested through experiments with the general public in the Tokyo area. Now, the phase II is ready: GlucoScanner can be miniaturized and manufactured, in order to be sent to practices, clinics, hospitals and private users for further testing.
In May we will be ready to start our pilot clinical study. Consequently, we want to proceed with a large-scale testing in medical facilities to improve our product performance and raise the user experience as much as possible.
We are currently scheduling clinical trials in different hospitals around the world (so far in more than 10 countries). Our project has been welcomed by many doctors and associations with our common objectives: to help diabetics improving their glucose management and to assist them in leading a healthier life.
We have managed to reduce the device size, which is now smaller than a mobile phone, in order to dramatically improve the diabetics’ life.
Explains Stefano Valenzi.
For further information, visit the website.